Abstract
Background
Diabetes mellitus (DM) is a major risk factor for cardiovascular mortality by increasing endothelial cell (EC) dysfunction and subsequently accelerating atherosclerosis. Extracellular-signal regulated kinase 5 (ERK5) is activated by steady laminar flow and regulates EC function by increasing eNOS expression and inhibiting EC inflammation. However, the role and regulatory mechanisms of ERK5 in EC dysfunction and atherosclerosis are poorly understood. Here, we report the critical role of the p90 ribosomal S6 kinase (p90RSK)/ERK5 complex in EC dysfunction in DM and atherosclerosis.
Methods and Results
Inducible EC-specific ERK5 knockout (ERK5-EKO) mice showed increased leukocyte rolling and impaired vessel reactivity. To examine the role of endothelial ERK5 in atherosclerosis, we used inducible ERK5-EKO-LDLR−/− mice and observed increased plaque formation. When activated, p90RSK associated with ERK5, and this association inhibited ERK5 transcriptional activity and up-regulated VCAM-1 expression. In addition, p90RSK directly phosphorylated ERK5 S496 and reduced eNOS expression. p90RSK activity was increased in diabetic mouse vessels, and FMK-MEA, a specific p90RSK inhibitor, ameliorated EC-leukocyte recruitment and diminished vascular reactivity in DM mice. Interestingly, in ERK-EKO mice, increased leukocyte rolling and impaired vessel reactivity were resistant to the beneficial effects of FMK-MEA, suggesting a critical role for endothelial ERK5 in mediating the salutary effects of FMK-MEA on endothelial dysfunction. FMK-MEA also inhibited atherosclerosis formation in ApoE−/− mice.
Conclusions
Our study highlights the importance of the p90RSK/ERK5 module as a critical mediator of EC dysfunction in DM and atherosclerosis formation, thus revealing a potential new target for therapeutic intervention.
Keywords: Diabetes mellitus, endothelial dysfunction, p90RSK, ERK5, signal transduction
Introduction
Endothelial dysfunction is commonly observed in patients with diabetes and atherosclerosis1, 2 and is recognized as an independent risk factor for the development of cardiovascular disease. Enhanced inflammation, generation of reactive oxygen species (ROS), and changes in vasoreactivity are characteristics of endothelial dysfunction3, 4. Hyperglycemia is a characteristic feature of DM and plays a critical role in DM-associated microvascular complications5, 6, including endothelial dysfunction1, 7. ERK5 activation induced by steady laminar flow (s-flow) inhibits leukocyte-endothelial interaction and adhesion molecule expression8–12. Importantly, ERK5 has not only a kinase domain but also a transcriptional activation domain, the latter of which is regulated by an intra-molecular interaction independent of ERK5 kinase activity11. ERK5/MEF2/KLF2 signaling is involved in the s-flow-mediated eNOS expression and anti-inflammatory effects13.
In this study, we focus on the following two goals to define novel roles for p90RSK and ERK5 in EC pathophysiology: 1) to determine the role of the p90RSK-ERK5 module in endothelial dysfunction and 2) to investigate the role of p90RSK activation (which causes endothelial dysfunction) on atherosclerosis formation.
Methods
Additional details of the experimental Procedures are included in the Supplemental information.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analysis was performed with the GraphPad Prism program, version 4.00 (GraphPad Software, Inc., CA). Nonparametric methods were used to analyze differences between independent groups. Differences between 2 groups were analyzed by Wilcoxon signed-rank test; between > 2 groups were analyzed by Kruskal-Wallis test, followed by Bonferroni multiple-comparison test. (1) the sample size, (2) number of repeated measurements per experiment unit including time intervals, and (3) where the correlation data come from, were listed in each figure and figure legend. P values less than 0.05 are accepted as being statistically significant and indicated by one asterisk (*). Two asterisks indicate the p value less than 0.01 (**). Since large numbers of statistical comparisons were performed, all at the 0.05 level of significance may result in the possibility of a type I error.
Results
High glucose and H2O2 synergistically inhibit ERK5-mediated functions in a p90RSK-dependent manner
Previously, we have reported that ROS inhibits ERK5 transcriptional activity14, 15. In addition, we also noted that p90RSK is activated by ROS16. Therefore, we asked if p90RSK inhibited ERK5 transcriptional activity in ECs. Since substantial evidence has implicated the role for H2O2 in promoting EC dysfunction and DM-associated cardiovascular complications3, 4, we specifically investigated if H2O2 inhibits ERK5 transcriptional activity by activating p90RSK14. First, in HUVECs, we found that H2O2-induced p90RSK activation preceded ERK5 activation (Fig.1A, C, D) and that dominant negative ERK5 had no effect on p90RSK kinase activation (Fig.S1A, B). These data suggest that p90RSK might negatively regulate ERK5 function in ECs in response to H2O2, despite the fact that ERK5 has been suggested to be upstream of p90RSK under certain conditions17.
We found that WT-p90RSK overexpression not only inhibited ERK5 transcriptional activity (measured by co-transfecting ECs with CA-MEK5α, a Gal4-ERK5 fusion construct, and a Gal4-driven luciferase reporter) but also enhanced H2O2-mediated inhibition of ERK5 transcriptional activity (Fig.1E). However, the inhibitory effect of H2O2 on ERK5 transcriptional activity was dose-dependently abolished by a highly selective inhibitor of p90RSK, fluoromethyl ketone-methoxyethylamine (FMK-MEA)18 (Fig.1F, S1C, and TableS1), suggesting the crucial role for p90RSK activation in ERK5 transcriptional activity. Because ERK5 enhances MEF2 activity and subsequently KLF2 promoter activity in ECs19, we also tested the effect of p90RSK activation in this context. Similar to the Gal4-ERK5 reporter, H2O2 inhibited ERK5-induced KLF2 promoter activity. Importantly, this inhibitory effect of H2O2 was completely reversed by FMK-MEA (Fig.1G), further demonstrating an inhibitory effect of p90RSK kinase activity on ERK5-regulated transcription.
Because H2O2 inhibits s-flow-induced ERK5 transcriptional activity, KLF2 promoter activity, and subsequent eNOS expression14, we next asked whether p90RSK mediates these inhibitory effects. ERK5 is activated by s-flow and regulates EC function by increasing eNOS and KLF2 expression and inhibiting EC inflammation13. Induction of the KLF2 and eNOS promoter activities by s-flow was counteracted by H2O2, but DN-p90RSK completely reversed this inhibitory effect (Fig.S1D). To model the potential effect of diabetes on p90RSK activation, we also investigated the effect of high glucose (25mM, HG) on endothelial p90RSK activation. We found that exposure to either HG (25mM) or low-dose H2O2 (20µM) by itself could not strongly activate p90RSK (Figs.S2A, B and data not shown). However, the combination of low-dose H2O2 (20µM) and HG strongly induced p90RSK activation (Figs.S2A and B). Mannitol substitution for D-glucose to control for osmotic changes was without effect. In addition, we found that the HG plus low H2O2 condition (HG/low H2O2) inhibited ERK5 transcriptional activity in a p90RSK-dependent manner (Fig.S2C). Therefore, we used the HG/low H2O2 condition as an in vitro model for studying a combined effect of high glucose and ROS (associated with diabetes) on ECs and analyzed the effect in the context of p90RSK activation. We also used advanced glycogen end-products (AGE) and found the involvement of p90RSK activation in AGE-mediated reduction of ERK5 transcriptional activity (Fig.S2D and E), further suggesting the role of endothelial p90RSK-ERK5 module in DM. In mouse endothelial cells isolated from lungs (MECs), HG/low H2O2 inhibited KLF2 mRNA expression, and this effect was reversed by FMK-MEA (Fig.1H). Moreover, FMK-MEA inhibited the HG/low H2O2-mediated increase in VCAM-1 mRNA (Fig.1I). Finally, overexpression of dominant negative p90RSK was found to counteract the negative and positive effects of HG/low H2O2 on eNOS and VCAM-1 protein levels, respectively (Figs.1J-M). Taken together, these data support a pro-inflammatory role for p90RSK, which is activated in ECs by stimuli associated with DM (HG and ROS) and which serves to counteract the anti-inflammatory program executed by ERK5.
Pro-inflammatory effects of p90RSK are mediated by complex formation with ERK5
To begin to explore the mechanism by which p90RSK negatively regulates ERK5 transcriptional activity, we first asked if p90RSK associates with ERK5. In HUVECs, endogenous p90RSK co-immunoprecipitated with anti-ERK5 but not with IgG control in a manner that was coincident with active but not inactive p90RSK (Fig.1A, B). Two-hybrid experiments indicated that both the NH2-terminal kinase (aa1-418) and COOH-terminal transcriptional activation domains (aa571-807) of ERK5 bound to p90RSK, whereas the central segment (aa412-577) did not (Fig.S3A). Consistent with the two-hybrid results, the COOH-terminal fragment (aa571-807) blocked the association between p90RSK and full-length ERK5 in a dose-dependent manner (Fig.2A). Importantly, this inhibitory ERK5 fragment abolished H2O2-induced reduction of ERK5 transcriptional activity, whereas the central ERK5 (aa412-577) fragment had no effect (Fig.2B). Taken together, these results indicate that inhibition of ERK5 transcriptional activity depends on p90RSK-ERK5 binding, in addition to p90RSK activation.
Next, to examine the role of p90RSK-ERK5 association in increased VCAM-1 expression, we infected MECs with an adenovirus expressing the ERK5 (aa571-807) fragment and found that it significantly blocked VCAM-1 expression induced by HG/H2O2 in MECs (Fig.2C, D). These data provide consistent evidence that p90RSK-ERK5 association is critical for regulation of VCAM-1 expression by p90RSK activation.
p90RSK inhibits ERK5 transcriptional activity by phosphorylating ERK5-S496
We have reported that p90RSK not only associates with ERK5 but also phosphorylates it at S49620. Our analysis using NetPhosK1.0 further identified ERK5-S433, -T475, -S486, and -S489 as potential phosphorylation sites, and in vitro kinase assays using GST-tagged ERK5 mutants suggested that T475 and S486 could also be phosphorylated by p90RSK (data not shown). To determine whether these potential phosphorylation sites are involved in ERK5 transcriptional activity, we tested if p90RSK could inhibit transcriptional activity of ERK5 mutants whose potential phosphorylation sites were substituted by Ala. Only ERK5-S496A was resistant to the inhibitory effect of p90RSK (Fig.2E), demonstrating that p90RSK regulates ERK5 transcriptional activity via S496 phosphorylation.
To investigate whether ERK5-S496 is actually phosphorylated by p90RSK in cells, we generated antibodies specific to ERK5 phosphorylated at S496 as described in methods. Western blotting analyses with this antibody show that overexpression of p90RSK stimulated the phosphorylation of WT but not S496A ERK5 (Fig.2F, G). In addition, in HUVECs phosphorylation of endogenous ERK5-S496 was induced by H2O2 and inhibited by FMK-MEA treatment (Fig.2H, I) or Ad-DN-p90RSK transduction (Fig.S3B, C).
To investigate the role of p90RSK-mediated ERK5 phosphorylation in the reduction of s-flow-induced eNOS expression by H2O2, we used an adenovirus expressing ERK5-S496A (Ad-ERK5-S496A). Of note, we used a relatively high concentration of H2O2 (400µM) in this set of experiments due to the protective effect of ERK5 overexpression on eNOS reduction, as described previously14. Ad-ERK5-S496A reversed the reduction of s-flow-induced eNOS expression by H2O2 (Fig. 2J, K). These results suggest that p90RSK-mediated ERK5-S496 phosphorylation is crucial for the reduced eNOS expression mediated by H2O2.
EC-specific ERK5 depletion induces EC dysfunction and accelerates atherosclerosis
Since systemic knockout of ERK5 is lethal in embryos21 and adults15, we generated tamoxifen (4-OHT:4-hydroxytamoxifen)-inducible EC-specific ERK5 knockout mice (ERK5-EKO) as described in the Methods section. Sustained reduction of endothelial ERK5 was confirmed by Western blotting using MECs two weeks after 4-OHT injection (Fig.3A). In the spleen lysate of inducible ERK5-EKO−/− mice, we found no reduction of ERK5 compared to that of the VE-Cad-CreERT2-WT control after two weeks of 4-OHT injection, also indicating the reduced ERK5 is endothelial specific (Fig.3B).
ERK5 has been shown to be a critical regulator of KLF2, which in turn regulates eNOS expression and counteracts EC inflammation13, 14 in vitro. We, therefore, assayed the expression of anti- and pro-inflammatory factors in inducible ERK5-EKO+/− mice after two weeks of 4-OHT injection. eNOS expression was decreased while the expression of VCAM-1 and E-selectin was increased in MECs isolated from 4-OHT-treated mice compared to that of vehicle-treated mice (Fig.3A). With regard to apoptosis, no difference was noted in the basal level of cleaved caspase-3 expression or TUNEL-positive cells in the two groups of mice (Fig.3A, S4A). To exclude possible deleterious effects of 4-OHT on ECs, we used non-inducible EC-specific ERK5 knockout mice (VE-Cad-Cre/ERK5flox/flox; non-inducible ERK5-EKO−/−) that were of the same age as the 4-OHT inducible animals. We found similar effects on eNOS, VCAM-1, and E-selectin expression as in the inducible ERK5-EKO+/− mice (Fig.S4B). Up to 6 months of age, we did not observe any differences in size or body weight between homo- or heterozygous ERK5-EKO mice and non-transgenic littermate control mice, and no notable differences were found on their development, life span, and tissue structures at a gross anatomical level. In addition, we found no differences in the expression of ERK5, eNOS, VCAM-1, E-selectin, total and phospho-p90RSK (Ser380) between vehicle- and 4-OHT-treated VE-Cad-CreERT2/WT mice (Fig.S4C).
To evaluate a functional role of the reduced endothelial ERK5, we studied leukocyte rolling and acetylcholine (Ach)-induced vasodilation in the mesentery of inducible ERK5-EKO+/− mice. Leukocyte rolling was increased in the 4-OHT-treated group compared to that of the vehicle-treated group (Fig.3D, and supplemental video 1). No changes were observed in venular diameter or shear rate under these conditions (Fig.3C). Ach-induced vasodilation was significantly decreased in both inducible heterozygous ERK5-EKO+/− and homozygous ERK5-EKO−/− mice compared to the 4-OHT-treated control VE-Cad-CreERT2/wild type mice (Fig.3E). It is remarkable that phenotypes with inducible KO of one allele and constitutive KO of both alleles are identical, suggesting that ECs are extremely sensitive to ERK5 dosage. EC-independent vasodilation by sodium nitroprusside (SNP) was indistinguishable between inducible ERK5-EKO and VE-Cad-CreERT2/WT mice (Fig.S4D), indicating the critical role of ERK5 in EC-mediated vasodilation.
To examine the role of endothelial ERK5 in atherosclerosis formation, inducible ERK5-EKO-LDLR−/− mice were fed with high cholesterol diet (HCD) for 16 weeks. Compared to the control mice, no difference either in body weight (Fig.S5A), glucose tolerance test (Fig.S5B), or plasma cholesterol level (Fig.S5C) in inducible ERK5-EKO−/−; LDLR−/− mice was noted. However, we observed a significant increase in both surface area and size of lesions in the aortic root of these mice compared to that of the control (Fig.3F). These data suggest a critical role of ERK5 in EC dysfunction and subsequent atherosclerosis formation.
p90RSK expression and phosphorylation are increased in DM mouse aorta
To confirm that diabetes increases endothelial p90RSK activation, we analyzed the localization and expression of both total and phospho-p90RSK (p-p90RSK) in en face preparations of mouse endothelium derived from streptozotocin (STZ)-induced diabetic mice (Fig.4A) using a laser scanning confocal microscope. The STZ effect in inducing diabetes in mice was confirmed by the increase in blood glucose levels. This increase was reduced to the normal level when STZ-injected mice were treated twice daily with insulin (Humalin N, 5 IU/kg) after 3 days of STZ injection (Fig.4B).
Fig.4A shows the effect of hyperglycemia on both p-p90RSK and total p90RSK expressions in vehicle-, STZ−, and STZ + insulin-treated mice in the same steady laminar flow area (greater curvature area at aortic arch). The anti-p-p90RSK staining signal was significantly increased in STZ treated mice. Note that both p-p90RSK (upper panels) and total p90RSK (Lower panels) are mainly localized in the nucleus. Based on fluorescence staining intensities, there was a significant decrease in p-p90RSK in aortae derived from insulin-treated diabetic mice compared to that of the untreated mice (Fig.4A, C-D). Furthermore, we detected the endothelial p90RSK activation in MECs isolated from STZ-treated mice by Western blotting and confirmed a significant increase in p90RSK activation compared with vehicle treated mice (Fig.4E). Taken together, these data suggest that the observed increase in p90RSK activation in STZ-treated mice is due to hyperglycemia.
FMK-MEA, a selective p90RSK inhibitor, reverses DM-mediated EC dysfunction
Leukocyte rolling and adhesion are characteristics of vascular inflammation, and vascular reactivity to ACh is an indicator of vascular function. Increased leukocyte rolling22 and decreased ACh-induced vasodilation23 in DM have been reported. In STZ-treated mice, leukocyte rolling was increased and ACh-induced vasodilation was dampened compared to those of the vehicle-treated mice (Fig.5A-C, and supplemental video 2). To study the involvement of p90RSK activation in the observed vascular inflammation and dysfunction in STZ-treated mice, FMK-MEA was used. FMK-MEA (Fig.S6A) is a more soluble and metabolically stable version of FMK19, a selective and irreversible inhibitor of p90RSK1, p90RSK2, and p90RSK4. To show the specificity of FMK-MEA, we used the Ambit/DiscoverX platform to screen 443 kinases and measured the apparent binding constant (Kd) to a given inhibitor. We found that all kinases except RSK1/4 CTD bound with Kd ≫ 1µM, which was carried out in vitro against recombinant kinase domains (TableS1). Treatment of mice with FMK-MEA at the highest dose of 50mg/kg inhibited p90RSK1 by >95% and p90RSK2 by ~80% in mouse heart tissue (Fig.S6B). First, we found that the increase of p90RSK activation in MECs isolated from STZ-treated mice was significantly inhibited by FMK-MEA treatment (Fig.4E). Next, we observed a dose-dependent inhibitory effect of FMK-MEA on leukocyte rolling in diabetic mice (Fig.5A-C, and supplemental video 2). The dose dependence of this effect correlated with p90RSK1/2 inhibition (Fig.S6B). Insulin treatment also reduced leukocyte rolling (Fig.5A-C, and supplemental video 2), in agreement with in vitro data suggesting that increased leukocyte rolling and adhesion is caused by high glucose24 and not by STZ side effects. FMK-MEA affected neither systemic leukocyte counts nor blood glucose levels (Fig.S6C, D), demonstrating that FMK-MEA’s effect on leukocyte rolling/adhesion is independent of glucose lowering, unlike insulin, and does not result from global inhibition of leukocyte trafficking. By examining ACh-induced vasodilation, a surrogate for EC function, we found that FMK-MEA treatment significantly reversed EC dysfunction induced by hyperglycemia (Fig.5D). Of note, vasodilation induced by sodium nitroprusside was the same in STZ-treated and control mice (Fig.S6E).
To determine the role of p90RSK activation in the expression of pro-inflammatory adhesion molecules and anti-inflammatory eNOS in DM mice, we quantified mRNA levels of VCAM-1, E-selectin, and eNOS in MECs isolated from STZ-induced DM or control mice. STZ diabetic mice exhibited a higher VCAM-1 and E-selectin mRNA expression but a lower eNOS mRNA expression, compared to that of the control mice (Fig.5E-G). Strikingly, FMK-MEA reversed the effect of STZ-induced DM on the expression of VCAM-1, E-selectin, and eNOS (Fig.5E-G). We confirmed that FMK-MEA treatment resulted in reduced E-selectin expression at the protein level as well (Fig.5H).
To confirm the importance of p90RSK activation in EC function in another DM model, we utilized C57BL/6J-Ins2Akita(Akita) mice, known to be hyperglycemic at 7 weeks of age25 (Fig.6A). Similar to STZ-treated mice, enhanced recruitment of leukocytes to EC and EC dysfunction were observed in Akita mice compared to age-matched littermate control (Fig. 6B, and supplemental video 3). FMK-MEA treatment significantly decreased leukocyte rolling and improved ACh-induced vasodilation (Fig.6B, C, and supplemental video 3). Using molecular approaches, we generated endothelial specific VE-Cad-CreERT2-WT-p90RSK-Tg mice (EC-WT-p90RSK-Tg) to further ascertain these observations. In the inducible EC-WT-p90RSK-Tg mice, we confirmed increasedp90RSK expression after 4-OHT treatment compared with VE-Cad-CreERT2-WT control mice (Fig.6D). We found that leukocyte rolling in the inducible EC-WT-p90RSK-Tg mice was significantly upregulated than VE-Cad-CreERT2-WT control mice after 4-OHT injection (Fig.6E, and supplemental video 4). Taken together, our findings indicate a critical role for p90RSK activation in EC inflammation and dysfunction in the diabetic state.
EC-specific ERK5 depletion eliminates the beneficial effect of FMK-MEA
To test whether ERK5 mediates the beneficial effects of FMK-MEA in DM-induced inflammatory events, we assayed leukocyte rolling and Ach-induced vasodilation in inducible ERK5-EKO−/− mice with STZ-induced diabetes. Leukocyte rolling was increased and Ach-induced vasodilation was decreased in 4-OHT treated mice (Fig.7A-C, and supplemental video 5). Interestingly, FMK-MEA had no effect on leukocyte rolling and vessel reactivity in this context (Fig.7A-C, and supplemental video 5), suggesting a critical role for endothelial ERK5 in mediating the salutary effects of FMK-MEA on DM-induced endothelial dysfunction.
FMK-MEA inhibits atherosclerosis formation
As p90RSK activation is critical for DM-mediated EC inflammation and dysfunction, processes well known to initiate atherogenesis1, 26, we explored the role for p90RSK activation in atherogenesis. Atherosclerosis was induced in ApoE−/− mice as described in the Methods27. With a normal chow diet and low-dose angiotensin II (Ang II), atherosclerosis was accelerated without abdominal aorta aneurysms (AAA). Under those conditions, FMK-MEA significantly inhibited the formation of atherosclerotic lesions (Fig.8A). No difference in plasma cholesterol levels was observed in experimental groups (Fig.S6F). With a high fat diet and high-dose Ang II, both atherosclerosis and AAA were noted (Fig.8B). Again, FMK-MEA inhibited atherosclerosis formation in the arch and upper part of the descending aorta (Fig.8B). However, no inhibitory effect of FMK-MEA was observed on AAA formation (data not shown).
DISCUSSION
We have identified two key molecules that are involved in DM-mediated EC dysfunction and a drug that disrupts the regulatory connections between these molecules. Our study strongly suggests that DM activates p90RSK, which directly inhibits the transcriptional activity of ERK5, an atheroprotective non-classical MAP kinase. This induces inflammatory responses in ECs and promotes vascular dysfunction. First, we found a significant increase in leukocyte rolling and reduction in vessel reactivity in mesenteric vessels of inducible ERK5-EKO mice. Next, increased p90RSK activity in ECs was induced by HG both in vivo and in vitro. FMK-MEA, a specific inhibitor of p90RSK, counteracted DM-mediated EC inflammation and dysfunction, indicating the key role of p90RSK activation in DM. Interestingly, FMK-MEA could not improve these conditions in ERK5-EKO mice, suggesting the critical role of ERK5 in FMK-MEA-mediated improvement of EC function. Last, we found that FMK-MEA significantly inhibited, and the depletion of endothelial ERK5 accelerated, atherosclerosis formation in ApoE−/− and LDL−/− mice, confirming the importance of the p90RSK-ERK5 module in clinically-relevant endpoints of atherosclerosis.
We think that these data provide strong evidence for the key role of the p90RSK-ERK5 module in endothelial dysfunction and atherosclerosis formation. Although the role of this module on endothelial dysfunction in vivo was further demonstrated by eliminating the beneficial effect of FMK-MEA in EC-specific ERK5 depletion mice, the role of endothelial ERK5 in p90RSK-mediated atherosclerosis formation remains unclear. Further investigation will be necessary to prove this.
An expanded Discussion section is available in the Online Data Supplement.
Supplementary Material
Epidemiological studies over the past decade have shown that diabetes (DM) significantly affects the process of atherosclerosis formation and following cardiovascular events. Endothelial cell (EC) dysfunction and inflammation are blamed for the pathogenesis of atherosclerosis and cardiovascular complications in diabetic patients, and anti-inflammatory therapy has gained increasing attention in the drug development for cardiovascular diseases. Voluminous evidence showing that diabetic condition activates proinflammatory signaling pathways, but little is known about diabetes-mediated inhibition of anti-inflammatory responses that are activated by factors such as steady laminar flow (s-flow). Our study strongly suggests that DM activates p90RSK, which directly inhibits s-flow-induced transcriptional activation of ERK5, an atheroprotective non-classical MAP kinase. This inhibition induces inflammatory responses in ECs and promotes EC dysfunction. FMK-MEA, a specific inhibitor of p90RSK, counteracted DM-mediated EC inflammation and dysfunction, suggesting p90RSK activation as a key harmful event in DM. Interestingly, FMK-MEA could not improve these conditions in endothelial specific ERK5 knockout mice, indicating a critical role of ERK5 in FMK-MEA-mediated improvement of EC function. FMK-MEA significantly inhibited, and the depletion of endothelial ERK5 accelerated, atherosclerosis formation in ApoE−/− and LDL−/− mice, confirming the importance of the p90RSK-ERK5 module in clinically-relevant endpoints of atherosclerosis. The p90RSK-ERK5 module should be an attractive drug target since it has unique features that distinguish it from other classical MAPK signaling. We believe that regulating ERK5 transcriptional activity is critical for controlling EC inflammation and dysfunction, which should provide a new therapeutic strategy for reducing atherosclerosis.
Acknowledgements
The authors thank Drs. Scott Cameron and Jane Sottile and Ms. Mary Jackson for critically reading our manuscript, and Dr. Cathy Tournier for providing ERK5flox/flox mice.
Funding Sources: This work is supported by grants from the America Heart Association to Dr. Le (Postdoctoral fellowship 10POST4360007), and Dr. Woo (Postdoctoral fellowship 0625957T, Scientist Development Grant 0930360N), and from the National Institutes of Health to Dr. Abe (HL-088637, HL-064839, and HL-077789), and Dr. Taunton (GM-071434). Dr. Abe is a recipient of Established Investigator Awards of the American Heart Association (0740013N).
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest Disclosures: J.T. is a cofounder of Principia Biopharma, which has licensed FMK-MEA.
References
- 1.Geraldes P, King GL. Activation of protein kinase c isoforms and its impact on diabetic complications. Circ Res. 2010;106:1319–1331. doi: 10.1161/CIRCRESAHA.110.217117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–1904. doi: 10.1161/CIRCULATIONAHA.105.563213. [DOI] [PubMed] [Google Scholar]
- 3.Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res. 2000;87:840–844. doi: 10.1161/01.res.87.10.840. [DOI] [PubMed] [Google Scholar]
- 4.Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (rage) and rage ligands. Diabetes. 2010;59:249–255. doi: 10.2337/db09-0801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241. doi: 10.1038/35025203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14–E22. doi: 10.1161/01.res.88.2.e14. [DOI] [PubMed] [Google Scholar]
- 7.Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, Hedrick CC. Hyperglycaemia-induced superoxide production decreases enos expression via ap-1 activation in aortic endothelial cells. Diabetologia. 2004;47:1727–1734. doi: 10.1007/s00125-004-1525-1. [DOI] [PubMed] [Google Scholar]
- 8.Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, Yang Y, Ulevitch RJ, Lee JD. Targeted deletion of bmk1/erk5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest. 2004;113:1138–1148. doi: 10.1172/JCI19890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gimbrone MA, Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000;902:230–239. doi: 10.1111/j.1749-6632.2000.tb06318.x. discussion 239–240. [DOI] [PubMed] [Google Scholar]
- 10.Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med. 2009;6:16–26. doi: 10.1038/ncpcardio1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Akaike M, Che W, Marmarosh NL, Ohta S, Osawa M, Ding B, Berk BC, Yan C, Abe J. The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (ppargamma1) mediates interaction with extracellular signal-regulated kinase 5 and ppargamma1 transcriptional activation: Involvement in flow-induced ppargamma activation in endothelial cells. Mol Cell Biol. 2004;24:8691–8704. doi: 10.1128/MCB.24.19.8691-8704.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Yamawaki H, Lehoux S, Berk BC. Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation. 2003;108:1619–1625. doi: 10.1161/01.CIR.0000089373.49941.C4. [DOI] [PubMed] [Google Scholar]
- 13.Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA, Jr, Garcia-Cardena G. Integration of flow-dependent endothelial phenotypes by kruppel-like factor 2. J Clin Invest. 2006;116:49–58. doi: 10.1172/JCI24787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Woo CH, Shishido T, McClain C, Lim JH, Li JD, Yang J, Yan C, Abe J. Extracellular signal-regulated kinase 5 sumoylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res. 2008;102:538–545. doi: 10.1161/CIRCRESAHA.107.156877. [DOI] [PubMed] [Google Scholar]
- 15.Itoh S, Ding B, Bains CP, Wang N, Takeishi Y, Jalili T, King GL, Walsh RA, Yan C, Abe J. Role of p90 ribosomal s6 kinase (p90rsk) in reactive oxygen species and protein kinase c {beta} (pkc-{beta})-mediated cardiac troponin i phosphorylation. J Biol Chem. 2005;280:24135–24142. doi: 10.1074/jbc.M413015200. [DOI] [PubMed] [Google Scholar]
- 16.Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC. Reactive oxygen species activate p90 ribosomal s6 kinase via fyn and ras. J Biol Chem. 2000;275:1739–1748. doi: 10.1074/jbc.275.3.1739. [DOI] [PubMed] [Google Scholar]
- 17.Ranganathan A, Pearson GW, Chrestensen CA, Sturgill TW, Cobb MH. The map kinase erk5 binds to and phosphorylates p90 rsk. Arch Biochem Biophys. 2006;449:8–16. doi: 10.1016/j.abb.2006.02.023. [DOI] [PubMed] [Google Scholar]
- 18.Cuello F, Snabaitis AK, Cohen MS, Taunton J, Avkiran M. Evidence for direct regulation of myocardial na+/h+ exchanger isoform 1 phosphorylation and activity by 90-kda ribosomal s6 kinase (rsk): Effects of the novel and specific rsk inhibitor fmk on responses to alpha1-adrenergic stimulation. Mol Pharmacol. 2007;71:799–806. doi: 10.1124/mol.106.029900. [DOI] [PubMed] [Google Scholar]
- 19.Kasler HG, Victoria J, Duramad O, Winoto A. Erk5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol. 2000;20:8382–8389. doi: 10.1128/mcb.20.22.8382-8389.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Le NT, Takei Y, Shishido T, Woo CH, Chang E, Heo KS, Lee H, Lu Y, Morrell C, Oikawa M, McClain C, Wang X, Tournier C, Molina CA, Taunton J, Yan C, Fujiwara K, Patterson C, Yang J, Abe J. P90rsk targets the erk5-chip ubiquitin e3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circulation research. 2012;110:536–550. doi: 10.1161/CIRCRESAHA.111.254730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Sohn SJ, Sarvis BK, Cado D, Winoto A. Erk5 mapk regulates embryonic angiogenesis and acts as a hypoxia- sensitive repressor of vascular endothelial growth factor expression. J Biol Chem. 2002;277:43344–43351. doi: 10.1074/jbc.M207573200. [DOI] [PubMed] [Google Scholar]
- 22.Booth G, Stalker TJ, Lefer AM, Scalia R. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase c in vivo. Diabetes. 2002;51:1556–1564. doi: 10.2337/diabetes.51.5.1556. [DOI] [PubMed] [Google Scholar]
- 23.Taylor PD, Wickenden AD, Mirrlees DJ, Poston L. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: Effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol. 1994;111:42–48. doi: 10.1111/j.1476-5381.1994.tb14021.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a nf-kb-dependent fashion. J Clin Invest. 1998;101:1905–1915. doi: 10.1172/JCI656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, mody4, distal to d7mit189 on chromosome 7 determines early-onset niddm in nonobese c57bl/6 (akita) mutant mice. Diabetes. 1997;46:887–894. doi: 10.2337/diab.46.5.887. [DOI] [PubMed] [Google Scholar]
- 26.Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and rage: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003;93:1159–1169. doi: 10.1161/01.RES.0000103862.26506.3D. [DOI] [PubMed] [Google Scholar]
- 27.Daugherty A, Manning MW, Cassis LA. Angiotensin ii promotes atherosclerotic lesions and aneurysms in apolipoprotein e-deficient mice. J Clin Invest. 2000;105:1605–1612. doi: 10.1172/JCI7818. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.